About the event

Held over a weekend, the event is structured around a series of exhibitions, workshops, and panel discussions. The exhibitions showcase a curated selection of photographs that tell compelling stories from various corners of the globe, each image accompanied by detailed narratives that provide context and deeper insight into the historical significance of the scenes depicted. These photographs are drawn from the archives of renowned photographers, as well as emerging talents, ensuring a blend of both classical and contemporary perspectives.

Cliff Palace, Colorado
Investor’s Toolkit: Key Ratios for Assessing Virax Biolabs Group Ltd (VRAX)’s Performance – DwinneX

Investor’s Toolkit: Key Ratios for Assessing Virax Biolabs Group Ltd (VRAX)’s Performance

Kevin Freeman

Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

Virax Biolabs Group Ltd (NASDAQ: VRAX) closed the day trading at $0.4 down -0.86% from the previous closing price of $0.41. In other words, the price has decreased by -$0.86 from its previous closing price. On the day, 0.1 million shares were traded. VRAX stock price reached its highest trading level at $0.4345 during the session, while it also had its lowest trading level at $0.395.

Ratios:

For a better understanding of VRAX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.13 and its Current Ratio is at 7.27. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.

Upgrades & Downgrades

In the most recent recommendation for this company, H.C. Wainwright on March 31, 2025, initiated with a Buy rating and assigned the stock a target price of $3.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRAX now has a Market Capitalization of 1743730 and an Enterprise Value of -2098791. For the stock, the TTM Price-to-Sale (P/S) ratio is 174.48 while its Price-to-Book (P/B) ratio in mrq is 0.31. Its current Enterprise Value per Revenue stands at -331.51 whereas that against EBITDA is 0.355.

Stock Price History:

The Beta on a monthly basis for VRAX is 1.69, which has changed by -0.79441625 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, VRAX has reached a high of $3.20, while it has fallen to a 52-week low of $0.35. The 50-Day Moving Average of the stock is -28.73%, while the 200-Day Moving Average is calculated to be -55.69%.

Shares Statistics:

Over the past 3-months, VRAX traded about 630.91K shares per day on average, while over the past 10 days, VRAX traded about 73780 shares per day. A total of 4.34M shares are outstanding, with a floating share count of 3.90M. Insiders hold about 10.09% of the company’s shares, while institutions hold 7.44% stake in the company. Shares short for VRAX as of 1763078400 were 21529 with a Short Ratio of 0.03, compared to 1760486400 on 15626. Therefore, it implies a Short% of Shares Outstanding of 21529 and a Short% of Float of 0.5499999999999999.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.